Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04448886 |
Title | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Sara Tolaney |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | United States | Details | |
University of Chicago Medical Center | Chicago | Illinois | 60637 | United States | Details | |
Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
DFCI @ Foxborough | Foxboro | Massachusetts | 02035 | United States | Details | |
DFCI @ Milford Regional Hospital | Milford | Massachusetts | 01757 | United States | Details | |
DF/BWCC in Clinical Affiliation with South Shore Hospital | South Weymouth | Massachusetts | 02190 | United States | Details | |
University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | United States | Details | |
University of Pennsylvania-Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | United States | Details |